Johnson & Johnson: holds a promising immune response
The company’s scientists randomly selected healthy adults between the ages of 18 and 55 years, and those 65 years of age or older to receive a high or low dose of the new vaccine (Ad26.COV2.S), and another placebo drug. Some of the participants in the age group were also selected. 18 to 55 years old to receive a second dose of the vaccine, according to Al-Arabia.
Most of the volunteers produced neutral antibodies that can be detected, and the researchers believe that they play an important role in defending the cells against the virus, after 28 days, according to the trial data.
By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-55 age group.
Data from the first and second phases of clinical trials show that a single injection of the vaccine “gives a sustained antibody”.
The company uses the technologies it used to develop the Ebola vaccine in its vaccine against Covid-19.
Unlike the vaccines from Pfizer and Moderna, which require two doses with an interval of three to four weeks, Johnson & Johnson requires only one dose This will simplify the logistics of healthcare providers.
The most common side effects were fever, fatigue, headache, muscle aches, and pain at the injection site, according to the trial data. Side effects were less common in the older age group who received only one dose of the vaccine, as well as those who received a lower dose of the vaccine, according to the data.